Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-nave patients with chronic hepatitis B

Gastroenterology

Volumn 143, Issue 3, 2012, Pages

  Lok, Anna S ^a   Trinh, Huy ^b   Carosi, Giampiero ^c   Akarca, Ulus S ^d   Gadano, Adrian ^e   Habersetzer, François ^f   Sievert, William ^g   Wong, David ^h   Lovegren, Meghan ⁱ   Cohen, David ⁱ   Llamoso, Cyril ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Pacific Health Foundation   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d EGE UNIVERSITY   (Turkey)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g MONASH UNIVERSITY   (Australia)

^h TORONTO WESTERN HOSPITAL   (Canada)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

ALT; Antiviral Therapy; Hepatitis B e Antigen; Nucleos(t)ide Analogue

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

EID: 84865490229     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.05.037     Document Type: Article

References (36)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
2. A.S. Lok, B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
3. A.S. Lok, F. Zoulim, S. Locarnini Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 2007 254 265 (Pubitemid 47171942)
4. M.A. Thompson, J.A. Aberg, P. Cahn Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 2010 321 333
5. J.J. Sung, J.Y. Lai, S. Zeuzem Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 48 2008 728 735
6. C.L. Lai, N. Leung, E.K. Teo A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 129 2005 528 536 (Pubitemid 41096641)
7. G. Woo, G. Tomlinson, Y. Nishikawa Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
8. T.T. Chang, C.L. Lai, Y.S. Kew Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
9. R.G. Gish, A.S. Lok, T.T. Chang Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 133 2007 1437 1444 (Pubitemid 350029745)
10. C.L. Lai, D. Shouval, A.S. Lok Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020 (Pubitemid 43357805)
11. P. Marcellin, E.J. Heathcote, M. Buti Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
12. E.J. Heathcote, E.J. Gane, R.A. de Man Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients with chronic hepatitis B (study 103) (abstr 477) Hepatology 52 2010 556A
13. P. Marcellin, M. Buti, Z. Krastev Continued efficacy and safety through 4 years of tenofovir disproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102) (abstr 476) Hepatology 52 2010 538A
14. E.J. Heathcote, P. Marcellin, M. Buti Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
15. P. Marcellin, M. Buti, E.J. Gane Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis (abstr 1375) Hepatology 54 2011 1011A
16. A. Snow-Lampart, B. Chappell, M. Curtis No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
17. D.J. Tenney, R.E. Rose, C.J. Baldick Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
18. P. Marcellin, E.J. Heathcote, A. Corsa No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection (abstr 238) Hepatology 54 2011 480A
19. M.P. Manns, U.S. Akarca, T.T. Chang Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901 Expert Opin Drug Saf 11 2012 361 368
20. S. Mauss, F. Berger, N. Filmann Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B J Hepatol 55 2011 1235 1240
21. A. Duarte-Rojo, E.J. Heathcote Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B Therap Adv Gastroenterol 3 2010 107 119
22. C.M. Lange, J. Bojunga, W.P. Hofmann Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function Hepatology 50 2009 2001 2006
23. J.M. Pawlotsky, G. Dusheiko, A. Hatzakis Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach Gastroenterology 134 2008 405 415 (Pubitemid 351181309)
24. P. Lampertico, R. Soffredini, M. Vigan 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice (abstr 1433) Hepatology 54 Suppl 1 2011 1041A
25. S. Zeuzem, E. Gane, Y.F. Liaw Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B J Hepatol 51 2009 11 20
26. S.K. Fung, P. Andreone, S.H. Han Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation J Hepatol 43 2005 937 943 (Pubitemid 41627977)
27. M.F. Yuen, E. Sablon, C.K. Hui Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791 (Pubitemid 32928004)
28. D. Shouval, U. Akarca, G. Hatzis Continued virologic and biochemical improvement through 96 weeks of entecavir treatment In HBeAg(-) chronic hepatitis B patients (study ETV-027) Hepatology 44 Suppl 2 2006 S21
29. R. Zoutendijk, J.G. Reijnders, A. Brown Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response Hepatology 54 2011 443 451
30. M.F. Yuen, W.K. Seto, J. Fung Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety Am J Gastroenterol 106 2011 1264 1271
31. N. Leung, C.Y. Peng, H.W. Hann Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir Hepatology 49 2009 72 79
32. G.K. Lau, T. Piratvisuth, K.X. Luo Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695 (Pubitemid 41007823)
33. R.P. Perrillo, C.L. Lai, Y.F. Liaw Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology 36 2002 186 194 (Pubitemid 34700777)
34. E.H. Buster, B.E. Hansen, G.K. Lau Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2009 2002 2009
35. C.J. Chen, H.I. Yang, J. Su Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73 (Pubitemid 43042691)
36. Y.F. Liaw, I.S. Sheen, C.M. Lee Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 2011 62 72